FTC order could ease biopharma competition
European Pharmaceutical Review
SEPTEMBER 4, 2023
The biopharma company will be required to seek prior approval before acquiring related products. to address the potential competitive harm Amgen’s $27.8 We believe the government can protect competition while enhancing the value of biotech M&A activity,” John Delacourt, Deputy General Counsel for BIO declared.
Let's personalize your content